Bone marrow assessment in Langerhans cell histiocytosis

Minkov, Milen; Pötschger, Ulrike; Grois, Nicole; Gadner, Helmut; Dworzak, Michael

doi:10.1002/pbc.21227

Cited by 40 publications

(44 citation statements)

References 12 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, in patients with LCH and bone marrow involvement, CD1a-positive cells are not consistently identified in the bone marrow (24,32,33). In several patients, exemplified by patients 1 and 3 in this report, we detected infiltration of LCH cells in the bone marrow and liver by the presence of BRAF V600E-positive cells.…”

Section: Discussionmentioning

confidence: 47%

Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes

et al. 2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 47%

Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes

et al. 2017

View full text Add to dashboard Cite

“…• Complete blood count (CBC) with differential; bone marrow aspirate and biopsy should be performed as well if there are signs of hematopoietic dysfunction [22].…”

Section: Laboratory Datamentioning

confidence: 99%

Langerhans Cell Histiocytosis

Green

Rodríguez‐Galindo

2013

Pediatric Head and Neck Tumors

View full text Add to dashboard Cite

“…As illustrated in case 2, current histologic approaches may be insufficiently sensitive to detect bone marrow involvement. 16,41 Based on qPCR of bone marrow aspirate of patients with BRAF-V600E LCH lesions, bone marrow infiltration by BRAF-V600E…”

Section: Therapeutic Strategies Consideration Of Specific Presentationsmentioning

confidence: 99%

How I treat Langerhans cell histiocytosis

Allen

Ladisch

McClain

2015

Blood

180

170

View full text Add to dashboard Cite

“Langerhans cell histiocytosis” (LCH) describes a spectrum of clinical presentations ranging from a single bone lesion or trivial skin rash to an explosive disseminated disease. Regardless of clinical severity, LCH lesions share the common histology of CD1a+/CD207+ dendritic cells with characteristic morphology among an inflammatory infiltrate. Despite historical uncertainty defining LCH as inflammatory vs neoplastic and incomplete understanding of mechanisms of pathogenesis, clinical outcomes have improved markedly over the past decades through cooperative randomized clinical trials based on empiric therapeutic strategies. Significant advances include recognition of high- and low-risk clinical groups defined by hematopoietic and/or hepatic involvement, and of the importance of optimal intensity and of duration of chemotherapy. Nevertheless, mortality of high-risk patients, disease recurrence, lack of robustly tested salvage strategies, and significant disease morbidity of both high- and low-risk patients remain challenges. Recent discovery of recurrent somatic mutations in mitogen-activated protein kinase pathway genes at critical stages of myeloid hematopoietic differentiation in LCH patients supports redefinition of the disease as a myeloproliferative disorder and provides opportunities to develop novel approaches to diagnosis and therapy.

show abstract

Bone marrow assessment in Langerhans cell histiocytosis

Abstract: The combination of conventional aspirate cytology with ICC (CD1a staining) appears to be the most reliable tool for bone marrow assessment in LCH.

Cited by 40 publications

References 12 publications

Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes

Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes

Langerhans Cell Histiocytosis

How I treat Langerhans cell histiocytosis

Contact Info

Product

Resources

About